CN110269861A - D-甘露糖在制备预防和治疗骨质疏松药物中的应用 - Google Patents
D-甘露糖在制备预防和治疗骨质疏松药物中的应用 Download PDFInfo
- Publication number
- CN110269861A CN110269861A CN201910621522.6A CN201910621522A CN110269861A CN 110269861 A CN110269861 A CN 110269861A CN 201910621522 A CN201910621522 A CN 201910621522A CN 110269861 A CN110269861 A CN 110269861A
- Authority
- CN
- China
- Prior art keywords
- mannose
- bone
- osteoporosis
- application
- rheological properties
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 42
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 15
- 206010030247 Oestrogen deficiency Diseases 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 210000002997 osteoclast Anatomy 0.000 claims abstract description 10
- 239000000047 product Substances 0.000 claims abstract description 10
- 230000037182 bone density Effects 0.000 claims abstract description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 5
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 5
- 238000000855 fermentation Methods 0.000 claims abstract description 5
- 230000004151 fermentation Effects 0.000 claims abstract description 5
- 230000036541 health Effects 0.000 claims abstract description 4
- 210000003275 diaphysis Anatomy 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 210000000952 spleen Anatomy 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 2
- 244000060011 Cocos nucifera Species 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- 229940028885 interleukin-4 Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 1
- 108010025832 RANK Ligand Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 108091006084 receptor activators Proteins 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 9
- 210000000689 upper leg Anatomy 0.000 description 6
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001599 osteoclastic effect Effects 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了D‑甘露糖在制备预防和治疗骨质疏松的药物、保健品或饮食补充剂的应用。从自然界植物中提取或利用生物发酵法产生的D‑甘露糖能够上调调节性T细胞与CD4+T细胞比例，抑制免疫炎症，抑制破骨细胞的活性及分化，增加增龄性骨质疏松小鼠及雌激素缺乏性骨质疏松小鼠的骨密度、骨体积分数、骨小梁厚度及数量，降低骨表面积与骨体积之比及骨小梁分离度，从而达到预防和治疗增龄性及雌激素缺乏性骨质疏松的效果。本发明产品D‑甘露糖，天然存在于植物及水果果皮中，具有来源广、易于产业化、安全有效、副作用小等优点，在预防和治疗增龄性及雌激素缺乏性骨质疏松中具有广阔的应用前景。
Description
本发明涉及一种药物的应用，具体涉及D-甘露糖在制备预防和治疗骨质疏松的药物、保健品或饮食补充剂的应用。
背景技术
骨质疏松是一种以骨量低下、骨的微结构损坏、导致骨脆性增加、易发生骨折为特征的全身性代谢性骨病，其临床表现为疼痛、脊柱变形及发生脆性骨折。2006年全国流行病学调查显示，50岁以上人群以椎骨和股骨颈骨密度值为基础的骨质疏松症总患病率为女性20.7％，男性14.4％。女性一生中发生骨质疏松的危险性(40％)高于乳腺癌、子宫内膜癌及卵巢癌的总和，男性一生发生骨质疏松的危险性(13％)高于前列腺癌。骨质疏松最严重的并发症是髋部骨折，一年内死于各种合并症者达20％，而存活者中约50％致残，生活不能自理。随着人类平均寿命的延长及老龄化社会的到来，骨质疏松症已成为人类日益重要的健康问题，其治疗花费高，并发症多，死亡率高，给家庭和社会带来沉重负担。
目前预防和治疗骨质疏松的药物主要分为抑制骨吸收类、促进骨合成类及骨矿化物类。抑制骨吸收类的药物有雌激素、双磷酸盐及降钙素等；促进骨合成类的药物有氟化物及甲状旁腺激素等；骨矿化物主要包括钙剂及维生素D等。雌激素能抑制骨吸收，但其除了作用于骨外，还作用于全身其他器官，增加了乳腺及子宫癌的风险；双磷酸盐长期应用会导致骨转换受到抑制，还会引起恶心、呕吐、腹痛、腹泻及造成颌骨骨髓炎等不良反应；降钙素能抑制骨吸收，但其不良反应包括面部或躯体皮肤潮红、恶心、呕吐等。氟化物的应用可以促进新骨形成，但长期应用会导致钙化缺陷；甲状旁腺素的不良反应包括恶心、头痛、关节痛等不适。钙剂的单纯应用效果不明显，其常见的不良反应有胃肠道刺激症状、便秘等；对于维生素D，过量补充可能引起维生素D中毒。由于目前抗骨质疏松药物的副作用限制了骨质疏松患者的长期使用。
因此，研发副作用小、能同时抑制骨吸收且促进骨合成的治疗骨质疏松药物具有深切的意义。
发明内容
针对现有预防和治疗骨质疏松药物存在的上述副作用及不足之处，本发明要解决的技术问题是提供一种有助于预防和治疗骨质疏松且副作用小的药物。旨在解决因现有预防和治疗骨质疏松药物副作用而限制了骨质疏松患者长期使用这些药物的问题。
为了解决上述技术问题，本申请采用如下技术方案予以实现：D-甘露糖在制备预防和治疗增龄性及雌激素缺乏性骨质疏松的药物、保健品或饮食补充剂的应用。
D-甘露糖通过上调调节性T细胞与CD4+ T细胞比例，抑制免疫炎症，抑制破骨细胞的活性及分化，增加增龄性骨质疏松小鼠及雌激素缺乏性骨质疏松小鼠的骨密度、骨体积分数、骨小梁厚度及数量，降低骨表面积与骨体积之比及骨小梁分离度，从而达到预防和治疗增龄性及雌激素缺乏性骨质疏松的效果。
所述D-甘露糖可以由植物水解、化学方法或者生物发酵法制备，所述植物水解是通过牙棕榈子、椰子壳，进行酸水解，所述的化学方法为用葡萄糖进行化学合成，所述的生物发酵法为微生物通过生物转化来制备D-甘露糖。
本发明产品D-甘露糖治疗骨质疏松与现有治疗骨质疏松的药物相比，具有以下优点：
本发明产品D-甘露糖，天然存在于植物及水果果皮中，具有来源广、易于产业化等优点，而且，D-甘露糖在国外已被广泛用作营养补充剂，表明其安全性和副作用小已得到肯定，故甘露糖在预防和治疗增龄性及雌激素缺乏性骨质疏松中具有广阔的开发应用前景。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案，下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍，显而易见地，下面描述中的附图仅仅是本发明的一些实施例，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图获得其他的附图。
图1.D-甘露糖显著增加增龄性骨质疏松小鼠及雌激素缺乏性骨质疏松小鼠的骨密度及改善骨质疏松小鼠的骨微结构。
具体实施方式
下面结合附图和实施例对本发明进行进一步说明。
实验过程包括如下几个方面：
(1)建立小鼠增龄性及雌激素缺乏性骨质疏松模型；
(2)实验组小鼠在饮水中额外加入甘露糖，对照组小鼠正常饮水；
(3)Micro CT分析补充甘露糖2月后，小鼠股骨、椎骨、下颌骨的变化；
(4)流式细胞术(FCM)、酶联免疫吸附测定(ELISA)、破骨细胞TRAP染色及小鼠肠道菌群多样性检测甘露糖预防和治疗骨质疏松的体内机制；
(5)培养骨髓间充质干细胞，探索甘露糖对干细胞直接促成骨作用。
具体实施步骤如下：
(1)预防和治疗骨质疏松的甘露糖溶液的制备：
称取19.8g甘露糖粉末，溶于100mL无菌蒸馏水中，制备成1.1M/L甘露糖溶液，然后进行高温高压蒸汽(102kPa，121℃，30分钟)灭菌。
(2)两种骨质疏松模型的建立：
12只代表增龄性骨质疏松6月龄的老年C57BL/6J小鼠，平均分为对照组和老年甘露糖组；12只代表雌激素缺乏性骨质疏松6周龄OVX后1个月的C57BL/6J小鼠，平均分为OVX组和OVX+甘露糖组；
(3)取各组小鼠的右侧股骨、椎骨及下颌骨去除软组织后，固定于4％多聚甲醛溶液24 小时，进行Micro CT扫描，检测甘露糖对小鼠股骨、椎骨及下颌骨的骨密度及骨微结构参数的影响，从而检测甘露糖对两种骨质疏松的预防和治疗效果，扫描参数为：电流为220μA，电压为60kV，曝光时间为1500ms；Micro CT扫描结果如下：
表1各组骨密度及骨微结构参数
注：*P＜0.05，**P＜0.01，与老年对照组相比；#P＜0.05，##P＜0.01，与VOX组相比；(n＝6；X±SD)
表1结果表明，增龄性骨质疏松(老年组)及雌激素缺乏性骨质疏松(OVX组)小鼠摄入甘露糖2个月后，股骨、椎骨及下颌骨的骨密度(BMD)显著增加；股骨和椎骨的骨体积与总体积之比(BV/TV)、骨小梁厚度(Tb.Th)、骨小梁数量(Tb.N)显著增加；骨表面积与体积之比(BS/BV)及骨小梁分离度(Tb.SP)显著下降，均有统计学差异。
(4)甘露糖摄入2个月后，小鼠股骨去除软组织后，放入10％EDTA脱钙液中脱钙2周，切取5μm厚的组织，用HE及TRAP染色试剂盒进行HE染色(从组织切片中检测甘露糖对小鼠骨组织微结构的改变)和TRAP染色(检测甘露糖对破骨细胞的抑制作用)，TRAP染色破骨细胞计数结果如下：
表2各组破骨细胞计数分析
注：**P＜0.01，与老年对照组相比；(n＝6；X±SD)
表2结果表明，摄入甘露糖后，破骨细胞面积与骨表面积之比(OC.S/BS)及单位面积破骨细胞数量显著下降，进一步表明甘露糖预防和治疗骨质疏松是通过抑制可以破骨细胞的生成来实现。
(5)分别于小鼠摄入甘露糖2周及2月后，手术摘取小鼠脾脏，将脾脏在70μm细胞筛网上研磨成细胞悬液，裂解红细胞，用含5％血清的1640洗涤细胞，制备脾脏单细胞；加入CD4、CD25抗体，避光孵育20分钟，用含1％血清的PBS洗涤细胞后，加入核内抗原专用固定破膜液，孵育30分钟，再用核内抗原专用破膜洗液洗涤细胞两次，加入Foxp3抗体，孵育30分钟，再用核内抗原专用破膜洗液洗涤细胞，再用含1％血清的PBS洗涤细胞后，重悬后用流式细胞仪获取分析调节性T(Treg)细胞，结果如下：
表3 Treg细胞与CD4+ T细胞比例
注：*P＜0.05，与老年对照组相比；#P＜0.05，与OVX组相比；(n＝6；X±SD)
表3表明摄入甘露糖2周后，调节性T细胞(Treg细胞)与CD4+ T细胞比例上调；2个月后调节性T细胞比例趋于稳定，表明甘露糖可以上调Treg细胞比例，进一步抑制免疫炎症和破骨细胞。
可以理解的是，以上关于本发明的具体描述，仅用于说明本发明而并非受限于本发明实施所描述的技术方案，本领域的普通技术人员应当理解，仍然可以对本发明进行局部修改或等同替换，以达到相同的技术效果；只要满足使用需要，都在本发明的保护范围之内。
Claims (7)
1.D-甘露糖在制备预防和治疗骨质疏松的药物、保健品或饮食补充剂的应用。
2.如权利要求1所述的应用，其特征在于：D-甘露糖能够抑制破骨细胞的生成。
3.如权利要求1所述的应用，其特征在于：D-甘露糖能够上调脾脏及骨髓中调节性T细胞与CD4+T细胞比例，抑制白细胞介素4(IL4)、白细胞介素6(IL6)、白细胞介素17(IL17)、肿瘤坏死因子及(TNFα)、核因子κB受体活化因子配体(RANKL)相关炎症因子的表达。
4.如权利要求1所述的应用，其特征在于：D-甘露糖能够抑制破骨细胞的生成。
5.如权利要求1所述的应用，其特征在于：D-甘露糖能够增加骨密度、骨体积分数、骨小梁厚度及数量，降低骨表面积与骨体积之比及骨小梁分离度，从而达到预防和治疗增龄性及雌激素缺乏性骨质疏松的作用。
6.如权利要求1所述的应用，其特征在于：所述D-甘露糖可以由植物水解、化学方法或者生物发酵法制备。
7.如权利要求6所述的应用，其特征在于：所述植物水解是通过牙棕榈子、椰子壳，进行酸水解，所述的化学方法为用葡萄糖进行化学合成，所述的生物发酵法为微生物通过生物转化来制备D-甘露糖。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910621522.6A CN110269861A (zh) | 2019-07-10 | 2019-07-10 | D-甘露糖在制备预防和治疗骨质疏松药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910621522.6A CN110269861A (zh) | 2019-07-10 | 2019-07-10 | D-甘露糖在制备预防和治疗骨质疏松药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110269861A true CN110269861A (zh) | 2019-09-24 |
Family
ID=67964213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910621522.6A Withdrawn CN110269861A (zh) | 2019-07-10 | 2019-07-10 | D-甘露糖在制备预防和治疗骨质疏松药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110269861A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070072244A1 (en) * | 2003-05-19 | 2007-03-29 | Quark Biotech, Inc. | Use of the endo-180 gene and polypeptide for diagnosis and treatment |
| CN107921083A (zh) * | 2015-05-27 | 2018-04-17 | 皮埃蒙特阿米阿伏伽德罗东方大学 | 在治疗骨质减少症和骨质疏松症中的B7h受体配体 |
-
2019
- 2019-07-10 CN CN201910621522.6A patent/CN110269861A/zh not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070072244A1 (en) * | 2003-05-19 | 2007-03-29 | Quark Biotech, Inc. | Use of the endo-180 gene and polypeptide for diagnosis and treatment |
| CN107921083A (zh) * | 2015-05-27 | 2018-04-17 | 皮埃蒙特阿米阿伏伽德罗东方大学 | 在治疗骨质减少症和骨质疏松症中的B7h受体配体 |
Non-Patent Citations (2)
| Title |
|---|
| SUN X. ET AL: "Protective effects of Dipsacus asper polysaccharide on osteoporosis in vivo by regulating RANKL/RANK/OPG/VEGF and PI3K/Akt/eNOS pathway", 《INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES》 * |
| 台立: "M2巨噬细胞分化为破骨细胞的机制研究", 《中国优秀博硕士学位论文全文数据库（硕士）医药卫生科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wong et al. | Quercetin as an agent for protecting the bone: a review of the current evidence | |
| Kadir et al. | Prevalence of Candida species in Turkish children: relationship between dietary ıntake and carriage | |
| Ortiz et al. | Therapeutic effects of citrus flavonoids neohesperidin, hesperidin and its aglycone, hesperetin on bone health | |
| CN102160614A (zh) | 一种具有提高人体免疫力和增强骨密度的复合制剂及其用途 | |
| JP5080284B2 (ja) | 骨疾患の予防及び／又は治療用医薬組成物、その組成物を含有する機能性食品、健康食品及び医薬製剤、並びに歯根−歯周組織形成促進剤 | |
| MacDonald et al. | Melatonin inhibits osteoclastogenesis and osteolytic bone metastasis: implications for osteoporosis | |
| CN110368402A (zh) | 间充质干细胞制剂及其制备方法和应用 | |
| CN109453188B (zh) | 一种沙虫多糖在制备防治骨质疏松药物中的应用 | |
| Chen et al. | Lactic acid bacteria: a promising tool for menopausal health management in women | |
| Taghsimi et al. | Efficiency and safety of dental implantation in the area of hyperdense jaw lesions: a narrative review | |
| CN101134051A (zh) | 酪酸梭菌、凝结芽孢杆菌、双歧杆菌在制备治疗肠易激综合征、冷凉泻、喝酒泻药物中的应用 | |
| CN110269861A (zh) | D-甘露糖在制备预防和治疗骨质疏松药物中的应用 | |
| CN101455704B (zh) | 一种预防和治疗骨质疏松的中药组合物及其制备方法 | |
| CN102579803A (zh) | 一种治疗化疗后白细胞减少症的药物及其制备方法 | |
| CN102106895A (zh) | 一种具有调节血脂功能的组合物 | |
| Ruan et al. | The antiresoptive effects of recombinant Lingzhi-8 protein against retinoic acid-induced osteopenia | |
| RU2149633C1 (ru) | Способ лечения иммунодефицитных состояний организма | |
| CN109529020A (zh) | 低剂量白细胞介素2在防治骨质疏松症中的新用途 | |
| Lai et al. | Lycium barbarum polysaccharide‐glycoprotein promotes osteogenesis in hPDLSCs via ERK activation | |
| CN109329207A (zh) | 一种抗肿瘤实验动物模型及其构建方法 | |
| CN109432075A (zh) | 间羟基苯丙酸在制备抗骨质疏松症药物中的应用 | |
| CN110200957A (zh) | 氟芬那酸在制备预防和治疗骨质疏松药物中的应用 | |
| CN111110698A (zh) | 牙髓间充质干细胞延缓女性卵巢早衰的方法 | |
| CN108888754A (zh) | 一种含乌苯美司和trail蛋白的抗肿瘤组合物及其应用 | |
| CN102008511A (zh) | 酪酸梭菌、凝结芽孢杆菌、双歧杆菌在制备治疗冷凉泻、喝酒泻药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190924 |
|
| WW01 | Invention patent application withdrawn after publication |